OPTIRAY 240 Rx
Generic Name and Formulations:
Ioversol 509mg/mL; soln for intravascular administration; contains organically bound iodine 240mg per mL.
Indications for OPTIRAY 240:
Cerebral angiography and venography. For contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.
Individualize. Visualization of carotid or vertebral arteries: 2–12mL, repeat as necessary. Aortic arch inj for simultaneous four vessel study: 20–50mL; total procedure doses should not exceed 200mL. Venography: 50–100mL per extremity; max 250mL. Head imaging: 100–250mL; max 250mL. Body imaging: Bolus inj: 35–100mL; Infusion: 70-200mL; max 250mL. IV urography: 75–100mL; may use higher dose of 2mL/kg (max 200mL) for optimum results.
See full labeling. Not for intrathecal use. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Risk of serious thromboembolic events (eg, MI, stroke), neurologic sequelae, including paralysis. Suspected thrombosis, phlebitis, severe ischemic disease, local infection: caution in venography. Advanced arteriosclerosis, severe hypertension, cardiac decompensation, senility, recent cerebral thrombosis/embolism, and migraine: use extreme caution in cerebral arteriography. Avoid angiography with homocystinuria. Renal or hepatic impairment. Anuria. CHF. Pulmonary hypertension. Chronic pulmonary emphysema. Dehydration. Multiple myeloma or other paraproteinemia. Homozygous sickle cell disease. Pheochromocytoma. Thyroid disorder. Diabetes. Myasthenia gravis. Anesthetized patients. Monitor blood pressure and ECG. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers.
Patients with hepatic or biliary disorder that have received cholecystographic agents recently; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Radiopaque contrast agent.
Nausea, headache, hypersensitivity; cardiovascular, CNS, respiratory, skin reactions, endocrine, others (see full labeling).
OPTIRAY 240: Bottles (50mL)—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 125mL)—20, RFID-Tagged syringes (125ml)—20; OPTIRAY 300: Bottles (50mL—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 100mL, 125mL)—20, RFID-Tagged syringes (100mL, 125mL)—20; OPTIRAY 320: Vials (20mL, 30mL)—25, Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (30mL, 50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder